News from Eisai Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 24, 2018, 19:34 ET Eisai and Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration...


May 17, 2018, 08:08 ET Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck

Eisai Inc. today announced the presentation of new data and analyses at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from...


Apr 19, 2018, 10:00 ET Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA

Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from...


Mar 30, 2018, 14:52 ET Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications

Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug...


Feb 15, 2018, 08:08 ET Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet

Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed...


Feb 05, 2018, 08:08 ET Eribulin Mesylate Nearly Doubles Overall Survival in Previously Treated Patients with Advanced Liposarcoma in Subanalysis Published in the Journal of Clinical Oncology

Eisai Inc. today announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribulin mesylate (marketed...


Jan 30, 2018, 08:00 ET Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer's Disease-associated Genetic Variants on Brain

Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer's disease-associated...


Jan 19, 2018, 08:08 ET Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma

Eisai Inc. announced today results from the independent imaging review (IIR) of the REFLECT study (Study 304), a Phase 3 trial evaluating...


Jan 09, 2018, 06:45 ET Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma

Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy...


Dec 08, 2017, 08:08 ET Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer Presented at the 2017 SABCS

Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in...


Dec 05, 2017, 13:28 ET Child Neurology Foundation and Eisai Announce New Transitions of Care Resources for Young People Living with Epilepsy

The Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy...


Nov 22, 2017, 09:30 ET Eisai Announces Presentations on Perampanel (marketed as FYCOMPA CIII) at the Annual Meeting of the American Epilepsy Society (AES)

Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These...


Oct 30, 2017, 07:55 ET New Data Highlight Innovative Ways to Assess Patients with Early Alzheimer's Disease and Later Stage Alzheimer's Disease Dementia

Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting,...


Oct 03, 2017, 08:00 ET Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., today announced that it has signed an agreement with Grupo...


Sep 26, 2017, 14:23 ET FDA Accepts Supplemental New Drug Application for Eisai's Lenvatinib for the Treatment of Liver Cancer

Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for...


Sep 25, 2017, 08:00 ET Michael Amoroso appointed Senior Vice President, Americas Commercial, Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., today announced the immediate appointment of Michael Amoroso as...


Sep 10, 2017, 08:30 ET Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial

Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating...


Sep 10, 2017, 06:15 ET Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study

Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was...


Aug 31, 2017, 16:03 ET Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress

Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European...


Aug 28, 2017, 07:55 ET Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial

Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with...


Jul 26, 2017, 18:40 ET FDA Approves Eisai's FYCOMPA® (perampanel) for Use as Monotherapy for the Treatment of Partial-Onset Seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for...


Jul 25, 2017, 07:55 ET Eisai Submits Supplemental New Drug Application to FDA for Lenvatinib in First-Line Hepatocellular Carcinoma

Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the...


Jul 17, 2017, 07:55 ET Eisai Announces New Research at the 2017 Alzheimer's Association International Conference® (AAIC®)

Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease...


Jun 21, 2017, 08:02 ET Eisai Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study will Continue as Planned Based on Interim Safety Analysis by Independent Data Monitoring Committee (DMC)

Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as...